Biblio

Found 39 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is P  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
D. J. Pulford, Harter, P., Floquet, A., Barrett, C., Suh, D. Hoon, Friedlander, M. Leonard, Arranz, J. Angel, Hasegawa, K., Tada, H., Vuylsteke, P., Mirza, M. R., Donadello, N., Scambia, G., Johnson, T., Cox, C., Chan, J. K., Imhof, M., Herzog, T. J., Calvert, P., Wimberger, P., Berton-Rigaud, D., Lim, M. Cheol, Elser, G., Xu, C. - F., and Bois, Adu, Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study., BMC Med Ethics, vol. 17, no. 1, p. 63, 2016.
E. Pujade-Lauraine, Mahner, S., Kaern, J., Gebski, V., Heywood, M., Vasey, P. A., Reinthaller, A., Vergote, I. B., Pignata, S., and Ferrero, A., A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer: CALYPSO study of the Gynecologic Cancer Intergroup., J Clin Oncol , vol. 27, no. 18, 2009.
E. Pujade-Lauraine, Wagner, U., Åvall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I. B., Pignata, S., Ferrero, A., Sehouli, J., Lortholary, A., Kristensen, G. B., Jackisch, C., Joly, F., Brown, C., Le Fur, N., and du Bois, A., Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse., J Clin Oncol, vol. 28, no. 20, pp. 3323-9, 2010.
E. Pujade-Lauraine, Hilpert, F., Weber, B., Reuss, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M. Raza, Follana, P., Bollag, D., and Ray-Coquard, I., Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial., J Clin Oncol, vol. 32, no. 13, p. 1308, 2014.
A. M. Poveda, Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I. B., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., and Pujade-Lauraine, E., Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial., J Clin Oncol, vol. 33, no. 32, p. 3838, 2015.
A. M. Poveda and Vermorken, J. B., The International Symposium on Advanced Ovarian Cancer. February 27, 2009, Spain., Int J Gynecol Cancer, vol. 19 Suppl 2, p. S1, 2009.
A. M. Poveda, Ten years of "Optimal Therapy in Advanced Ovarian Cancer. Update" meeting, Int J Gynecol Cancer, vol. 18 Suppl 1, pp. 67-70, 2008.
C. Pisano, Morabito, A., Sorio, R., Breda, E., Lauria, R., Gebbia, V., Scaltriti, L., Scalone, S., Zagonel, V., Greggi, S., Beneduce, G., Losito, S., Gallo, C., Di Maio, M., Forestieri, V., and Pignata, S., A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial, Cancer Chemother Pharmacol, vol. 64, pp. 1021-7, 2009.
S. Pilotti, Oggionni, M., Bohm, S., Pierotti, M. A., and Zunino, F., ICON3 and chemotherapy for ovarian cancer, Lancet, vol. 360, pp. 2087-8; author reply 2088, 2002.
S. Pignata, Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., Lombardi, A. V., Febbraro, A., Scollo, P., Ferro, A., Tamberi, S., Brandes, A., Ravaioli, A., Valerio, M. R., Aitini, E., Natale, D., Scaltriti, L., Greggi, S., Pisano, C., Lorusso, D., Salutari, V., Legge, F., Di Maio, M., Morabito, A., Gallo, C., and Perrone, F., Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial, J Clin Oncol, vol. 29, pp. 3628-35, 2011.
S. Pignata and Vermorken, J. B., Ovarian cancer in the elderly., Crit Rev Oncol Hematol, vol. 49, no. 1, pp. 77-86, 2004.
S. Pignata, De Placido, S., Biamonte, R., Scambia, G., Di Vagno, G., Colucci, G., Febbraro, A., Marinaccio, M., Lombardi, A. V., Manzione, L., Carteni, G., Nardi, M., Danese, S., Valerio, M. R., De Matteis, A., Massidda, B., Gasparini, G., Di Maio, M., Pisano, C., and Perrone, F., Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study, BMC Cancer, vol. 6, p. 5, 2006.
S. Pignata, Scambia, G., Savarese, A., Breda, E., Sorio, R., Pisano, C., Lorusso, D., Cognetti, F., A. Lombardi, V., Gebbia, V., Scollo, P., Morabito, A., Signoriello, G., and Perrone, F., Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial, Oncology, vol. 76, pp. 49-54, 2009.
S. Pignata, Breda, E., Scambia, G., Pisano, C., Zagonel, V., Lorusso, D., Greggi, S., De Vivo, R., Ferrandina, G., Gallo, C., and Perrone, F., A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study, Crit Rev Oncol Hematol, vol. 66, pp. 229-36, 2008.
S. Pignata, Scambia, G., Savarese, A., Breda, E., Scollo, P., De Vivo, R., Rossi, E., Gebbia, V., Natale, D., Del Gaizo, F., Naglieri, E., Ferro, A., Musso, P., D'Arco, A. M., Sorio, R., Pisano, C., Di Maio, M., Signoriello, G., Annunziata, A., Perrone, F., and Investigators, M. I. T. O., Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial, BMC Cancer, vol. 6, p. 202, 2006.
S. Pignata, Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., Cormio, G., Sorio, R., Cavazzini, M. G., Ferrandina, G., Breda, E., Murgia, V., Sacco, C., Cinieri, S., Salutari, V., Ricci, C., Pisano, C., Greggi, S., Lauria, R., Lorusso, D., Marchetti, C., Selvaggi, L., Signoriello, S., Piccirillo, M. C., Di Maio, M., Perrone, F., Cancer, M. Italian Tr, Sein, Gd'Investig, Oncology, M. Negri Gyne, Groups, E. Network of, and Investigators, G. Cancer Int, Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, vol. 15, pp. 396-405, 2014.
M. J. Piccart, Stuart, G. C. E., Cassidy, J., Bertelsen, K., Parmar, M. K. B., Eisenhauer, E., Kaye, S. B., Tropé, C. G., Swenerton, K. D., Harper, P., and Vermorken, J. B., Intergroup collaboration in ovarian cancer: a giant step forward., Ann Oncol, vol. 10 Suppl 1, pp. 83-6, 1999.
M. J. Piccart, Bertelsen, K., Stuart, G. C. E., Cassidy, J., Mangioni, C., Simonsen, E., James, K., Kaye, S. B., Vergote, I. B., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Tropé, C. G., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. - A., Lhoas, F., Lidvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Pecorelli, S., Baron, B., and McGuire, W. P., Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer, Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 144-8, 2003.
M. J. Piccart, Bertelsen, K., Stuart, G. C. E., Cassidy, J., Mangioni, C., Simonsen, E., James, K., Kaye, S. B., Vergote, I. B., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Tropé, C. G., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. - A., Lhoas, F., Lidvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Pecorelli, S., Baron, B., and McGuire, W. P., Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer., Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 144-8, 2003.
M. J. Piccart, Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Simonsen, E., Stuart, G. C. E., Kaye, S. B., Vergote, I. B., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Tropé, C. G., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. - A., Lhoas, F., Lindvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Baron, B., and Pecorelli, S., Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results, J Natl Cancer Inst, vol. 92, pp. 699-708, 2000.
M. J. Piccart, McGuire, W. P., and Group, G. Oncology, ICON2 trial. EORTC-GCCG, NOCOVA, NCI-C, Scottish groups, and GOG., Lancet, vol. 353, p. 587; author reply 588, 1999.
M. J. Piccart, Bertelsen, K., James, K., Cassidy, J., Mangioni, C., Simonsen, E., Stuart, G. C. E., Kaye, S. B., Vergote, I. B., Blom, R., Grimshaw, R., Atkinson, R. J., Swenerton, K. D., Tropé, C. G., Nardi, M., Kaern, J., Tumolo, S., Timmers, P., Roy, J. - A., Lhoas, F., Lindvall, B., Bacon, M., Birt, A., Andersen, J. E., Zee, B., Paul, J., Baron, B., and Pecorelli, S., Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results., J Natl Cancer Inst, vol. 92, no. 9, pp. 699-708, 2000.
M. J. Piccart, Floquet, A., Scarfone, G., Willemse, P. H., Emerich, J., Vergote, I. B., Giurgea, L., Coens, C., Awada, A., and Vermorken, J. B., Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy, Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 196-203, 2003.
J. Pfisterer, Harter, P., Canzler, U., Richter, B., Jackisch, C., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., du Bois, A., Committee, A. G. O. Ovarian, and Group, A. G. O. Ovarian Ca, The role of surgery in recurrent ovarian cancer, Int J Gynecol Cancer, vol. 15 Suppl 3, pp. 195-8, 2005.
J. Pfisterer, Plante, M., Vergote, I. B., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G. C. E., Kimmig, R., Olbricht, S., Le, T., Emerich, J., Kuhn, W., Bentley, J., Jackisch, C., Lück, H. - J., Rochon, J., Zimmermann, A. Hayden, and Eisenhauer, E., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG., J Clin Oncol, vol. 24, no. 29, pp. 4699-707, 2006.

Pages